•
LR
LRMR
Larimar Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
275.86M
Volume
530.20K
52W High
$5.37
52W Low
$1.61
Open
$0.00
Prev Close
$3.20
Day Range
0.00 - 0.00
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Latest News
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
Benzinga•Oct 16
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
Benzinga•Oct 16
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Benzinga•Oct 16
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
Benzinga•Sep 29
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
GlobeNewswire Inc.•Sep 29
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire Inc.•Sep 28
Larimar Beats Q2 Loss Estimates
The Motley Fool•Aug 14
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Benzinga•Jul 31